The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification.

Tandem Diabetes Care has secured a new FDA clearance for its insulin dose-calculating algorithm, opening up its use to adults with Type 2 diabetes. The Control-IQ+ program—now with the added ...

Diabetes technology innovators gathered last week for the Advanced Technologies and Treatments for Diabetes Conference (ATTD 2026).

The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...

Researchers found that the risk of type 2 diabetes varies among young adults. Those with high fasting glucose who qualified for GLP-1 treatment had a higher risk of type 2 diabetes, suggesting that ...

The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...